SAD-products | 2007 | 2010 |
---|---|---|
Dangerous drugs code | ||
Adrenalin | 2 | 11 |
KCl infusion* | 10 | 1 |
Suxameton* | 4 | 4 |
Strength colour code | ||
Na-Bicarbonat | 1 | 6 |
Bupivacain | 5 | 2 |
Bupivacain morfin | 2 | 2 |
Fenemal | 0 | 2 |
Glukose | 15 | 12 |
Heparin | 3 | 0 |
Lidocain | 15 | 3 |
Lidocain-adrenalin | 5 | 1 |
Lidocain-noradrenalin | 1 | 0 |
Morfin | 9 | 5 |
NaCl | 4 | 2 |
NaCl hyperton* | 0 | 1 |
Petidin | 1 | 2 |
Suxameton* | 4 | 4 |
Tablets | 2 | 2 |
Dilution code | ||
Na-Bicarbonat concentrate | 0 | 1 |
Glycerylnitrat | 0 | 7 |
Magnesium sulfat | 2 | 0 |
NaCl hyperton* | 0 | 1 |
KCl infusion* | 10 | 1 |
Other features | ||
Atropin | 0 | 6 |
Elektrolyt infusion | 8 | 15 |
Calciumchlorid | 1 | 0 |
Efedrin | 5 | 7 |
KCl oral solution | 7 | 0 |
Kodein oral solution | 1 | 0 |
Metaoxedrin | 2 | 3 |
Noradrenalin | 0 | 9 |
Tiomebumal-Na | 0 | 1 |
Tablets | 7 | 3 |
Suppositories | 0 | 3 |
Total number including double features | 126 | 117 |
The products are listed according to features introduced to their specific label design. Only injections, infusions and oral solutions are specified. Tablets and suppositories are listed as generic groups including different drugs.
*Products with double features (more than one feature in the design) that are accounted for twice in the table.